Abstract
Purpose
There is a lack of study concerning expression of Topoisomerase IIα (Topo IIα) and long-term results in colorectal cancer patients. We aimed to investigate the relationship between expression of Topo IIα and clinicopathological parameters including overall survival in colorectal cancer.
Methods
Paraffin-fixed specimens from a large prospective cohort of colorectal cancer patients who had been followed up for 4 years were assayed immunohistochemically.
Results
Of 490 colorectal cancer patients accessible for Topo IIα expression, expression of Topo IIα was scored as (−) in 4 (0.8%) patients, (+) in 41 (8.4%) patients, (++) in 396 (80.8%) patients, and (+++) in 49 (10.0%) patients. Overexpression of Topo IIα was found to be related with lower T stage (p = 0.042), lower N stage (p = 0.038), and a lower incidence of recurrence with nearly significance (p = 0.053). Kaplan–Meier analyses showed that overexpression of Topo IIα was related with prolonged overall survival (p = 0.022) and disease-free survival (p = 0.036). Multivariate analyses showed that elevated serum CEA (p < 0.001), elevated serum CA199 (p = 0.002), poor differentiation (p = 0.001), advanced Dukes stage (p < 0.001), and lower expression of Topo IIα (p = 0.017) were independent predictive factors for poor prognosis.
Conclusions
Topo IIα expression is a valuable prognostic indicator for colorectal cancer and would be useful in treatment selection for early colorectal cancer and malignant colorectal polyps resected under endoscopy, especially when it is used in combination with serum CEA, CA199, and differentiation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Le Pessot F, Michel P, Paresy M, Lemoine F, Hellot MF, Paillot B et al (2001) Cell proliferation in colorectal adenocarcinomas: comparison between Ki-67 immunostaining and bromodeoxyuridine uptake detected by immunohistochemistry and flow cytometry. Pathol Res Pract 197:411–418
Haq AI, Schneeweiss J, Kalsi V, Arya M (2009) The Dukes staging system: a cornerstone in the clinical management of colorectal cancer. Lancet Oncol 10:1128
Ahmed IA, Kelly SB, Anderson JJ, Angus B, Challen C, Lunec J (2008) The predictive value of p53 and p33(ING1b) in patients with Dukes’C colorectal cancer. Colorectal Dis 10:344–351
Theodoropoulos GE, Karafoka E, Papailiou JG, Stamopoulos P, Zambirinis CP, Bramis K et al (2009) P53 and EGFR expression in colorectal cancer: a reappraisal of ‘old’ tissue markers in patients with long follow-up. Anticancer Res 29:785–791
NCCN Clinical Practice Guidelines in Oncology. V.2.2011 (Colon cancer, Rectal cancer)
Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979–994
Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440
Shagisultanova EI, Piao Z, Li HR, Malkhosyan SR (2004) Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett 216:221–226
Saxena D, Yiu GK, Ni X, Huang KC, Mantovani R, Jacquemin-Sablon AG et al (2004) Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line. Gene 342:145–155
Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M (2004) Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35:745–751
Martincic D, Hande KR (2005) Topoisomerase II inhibitors. Canc Chemother Biol Response Modif 22:101–121
AJCC (American Joint Committee on Cancer) (2002) Cancer staging manual, 6th edn. Springer, New York
Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN et al (2009) Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett 276:228–238
Ou XL, Sun WH, Xu M, Cao DZ, Yu Q, Yu T et al (2005) Expression of glutathione S-transferase-pi and DNA topoisomerase II alpha and their implications in colorectal carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi 8:524–527
Giltnane JM, Rimm DL (2004) Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1:104–111
Akbari RP, Wong WD (2003) Endorectal ultrasound and the preoperative staging of rectal cancer. Scand J Surg 92:25–33
Chok KS, Law WL (2007) Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer. World J Surg 31:1485–1490
Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA et al (1991) Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51:6592–6595
Kim R, Ohi Y, Inoue H, Toge T (1999) Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res 19:5393–5398
Acknowledgments
This study was supported by a grant from the National Natural Science Fund of China (No. 30973460) and Natural Science Fund of the Science and Technology Commission of Shanghai Municipality (key projects; No. 07DZ1950). We appreciate Zhi Hong Liu for helping us in collecting clinicopathological data and enforcing follow-up.
Conflicts of interest statement
No conflicts of interest exist in the submission of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Xian Hua Gao, Zhi Qi Yu, and Chang Zhang contributed equally to this article.
Rights and permissions
About this article
Cite this article
Gao, X.H., Yu, Z.Q., Zhang, C. et al. DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner. Int J Colorectal Dis 27, 429–435 (2012). https://doi.org/10.1007/s00384-011-1346-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-011-1346-x